Understanding the Market | LAEKNA-B surged over 11% in early trading as overnight US stocks in the weight loss drug sector rose broadly. The company is conducting clinical cooperation with Eli Lilly on a new weight loss drug
LAEKNA-B surged over 11% in early trading, and as of the time of writing, it has risen 9.79% to HKD 17.04, with a trading volume of HKD 30.7419 million. On the news front, U.S. stocks related to weight loss drugs saw a broad increase on Tuesday, with Eli Lilly rising nearly 5%, Viking Therapeutics up nearly 3%, and Novo Nordisk up nearly 2%, following President Biden's proposal to cover weight loss medications under Medicare and Medicaid. Notably, on November 20, LAEKNA announced that it had reached a global clinical collaboration agreement with Eli Lilly, which will be responsible for conducting a Phase I clinical study of LAE102, a weight loss drug developed by LAEKNA, in the United States and will bear the related costs. It is reported that LAE102 is a monoclonal antibody independently developed to target Act RIIA, a receptor that plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown effects of increasing muscle and reducing fat. Great Wall Securities previously indicated that the commercialization of core pipelines LAE002 and LAE001 is approaching, and the self-developed pipeline represented by the muscle-building and fat-reducing drug LAE102 has good innovative prospects. The company is optimistic about the future commercialization development of its products
According to Zhitong Finance APP, LAEKNA-B (02105) rose over 11% in early trading, and as of the time of writing, it has increased by 9.79%, trading at HKD 17.04, with a transaction volume of HKD 30.7419 million.
In terms of news, U.S. stocks related to weight loss drugs saw a broad increase on Tuesday, with Eli Lilly rising nearly 5%, Viking Therapeutics up nearly 3%, and Novo Nordisk up nearly 2%, following President Biden's proposal for Medicare and Medicaid to cover weight loss medications. Notably, on November 20, LAEKNA announced that the company had reached a global clinical cooperation agreement with Eli Lilly, which will be responsible for conducting a Phase I clinical study of LAEKNA's weight loss drug LAE102 in the United States and will bear the related costs.
It is reported that LAE102 is a self-developed monoclonal antibody targeting Act RIIA, which plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown effects of increasing muscle and reducing fat. Great Wall Securities previously indicated that the core pipeline LAE002 and LAE001 are approaching commercialization, and the self-developed pipeline represented by the muscle-building and fat-reducing drug LAE102 has good innovative prospects. The company is optimistic about the future commercialization development of its products